Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteer between 6 - 35 months old; Term birth; Birth weight \>2500g;~* Proven legal identity;~* Written consent of the guardian(s) of the volunteer;~Exclusion Criteria:~* Received seasonal influenza vaccine in the current year;~* Suffering from seasonal influenza in the past 6 moths;~* Axillaty temperature \> 37.0 °C;~* History of allergy to any vaccine or vaccine ingredient;~* History of serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc;~* Autoimmune disease or immunodeficiency;~* Congenital malformation, developmental disorders;~* Severe malnutrition;~* Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders;~* History of epilepsy (except febrile seizures occurred \< 2 years of age or pure epilepsy occurred within the past 3 years that does not need treatment)~* Chronic diseases (e.g., viral hepatitis, tuberculosis, diabetes, blood diseases, or neurological disorders)~* Acute disease or acute stage of chronic disease;~* Receipt of any of the following products:~  1. Any subunit vaccine or inactivated vaccine (e.g., pneumococcal vaccine) or treatment of allergy within 14 days prior to study entry;~ 2. Any live attenuated vaccine within 30 days prior to study entry;~ 3. Any other investigational medicine(s) or vaccine within 30 days prior to study entry;~ 4. Blood product within 3 months prior to study entry;~ 5. Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry;~* Participate or will participate in other clinical trial(s) during this study;~* Based on the judgment of investigator(s) or the Ethic Committee, there was any condition indicating that the subject should be excluded;

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- Experimental group-phase Ⅰ (Type: EXPERIMENTAL): Quadrivalent influenza vaccine
- Experimental group-phase Ⅲ (Type: EXPERIMENTAL): Quadrivalent influenza vaccine
- Control group 1-phase Ⅲ (Type: ACTIVE_COMPARATOR): Trivalent influenza vaccine (contains B/Victoria strain)
- Control group 2-phase Ⅲ (Type: ACTIVE_COMPARATOR): Trivalent influenza vaccine (contains B/Yamagata strain)

Based on this trial design, predict the completion outcome and termination type (if applicable).